Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) EBIT Margin (2019 - 2025)

Cyclerion Therapeutics has reported EBIT Margin over the past 6 years, most recently at 114.97% for Q3 2025.

  • Quarterly results put EBIT Margin at 114.97% for Q3 2025, up 46647.0% from a year ago — trailing twelve months through Sep 2025 was 127.25% (up 292687.0% YoY), and the annual figure for FY2024 was 181.4%, changed.
  • EBIT Margin for Q3 2025 was 114.97% at Cyclerion Therapeutics, up from 1797.85% in the prior quarter.
  • Over the last five years, EBIT Margin for CYCN hit a ceiling of 27.8% in Q4 2024 and a floor of 21604.84% in Q1 2021.
  • Median EBIT Margin over the past 4 years was 1798.77% (2025), compared with a mean of 3505.29%.
  • Biggest five-year swings in EBIT Margin: crashed -1957437bps in 2021 and later soared 1977868bps in 2022.
  • Cyclerion Therapeutics' EBIT Margin stood at 2690.06% in 2021, then plummeted by -63bps to 4389.87% in 2022, then skyrocketed by 101bps to 27.8% in 2024, then tumbled by -514bps to 114.97% in 2025.
  • The last three reported values for EBIT Margin were 114.97% (Q3 2025), 1797.85% (Q2 2025), and 1798.77% (Q1 2025) per Business Quant data.